[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse TIMP1

Summary
SymbolTIMP1
NameTIMP metallopeptidase inhibitor 1
Aliases TIMP; CLGI; tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor) ......
Chromosomal LocationXp11.3-p11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted
Domain PF00965 Tissue inhibitor of metalloproteinase
Function

Metalloproteinase inhibitor that functions by forming one to one complexes with target metalloproteinases, such as collagenases, and irreversibly inactivates them by binding to their catalytic zinc cofactor. Acts on MMP1, MMP2, MMP3, MMP7, MMP8, MMP9, MMP10, MMP11, MMP12, MMP13 and MMP16. Does not act on MMP14. Also functions as a growth factor that regulates cell differentiation, migration and cell death and activates cellular signaling cascades via CD63 and ITGB1. Plays a role in integrin signaling. Mediates erythropoiesis in vitro; but, unlike IL3, it is species-specific, stimulating the growth and differentiation of only human and murine erythroid progenitors.

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001667 ameboidal-type cell migration
GO:0002576 platelet degranulation
GO:0006509 membrane protein ectodomain proteolysis
GO:0006887 exocytosis
GO:0007229 integrin-mediated signaling pathway
GO:0007565 female pregnancy
GO:0007566 embryo implantation
GO:0007568 aging
GO:0009894 regulation of catabolic process
GO:0009895 negative regulation of catabolic process
GO:0010466 negative regulation of peptidase activity
GO:0010951 negative regulation of endopeptidase activity
GO:0022617 extracellular matrix disassembly
GO:0030198 extracellular matrix organization
GO:0030336 negative regulation of cell migration
GO:0031329 regulation of cellular catabolic process
GO:0031330 negative regulation of cellular catabolic process
GO:0033619 membrane protein proteolysis
GO:0040013 negative regulation of locomotion
GO:0042176 regulation of protein catabolic process
GO:0042177 negative regulation of protein catabolic process
GO:0043062 extracellular structure organization
GO:0043434 response to peptide hormone
GO:0043900 regulation of multi-organism process
GO:0043901 negative regulation of multi-organism process
GO:0044706 multi-multicellular organism process
GO:0045055 regulated exocytosis
GO:0045861 negative regulation of proteolysis
GO:0051043 regulation of membrane protein ectodomain proteolysis
GO:0051045 negative regulation of membrane protein ectodomain proteolysis
GO:0051216 cartilage development
GO:0051271 negative regulation of cellular component movement
GO:0051346 negative regulation of hydrolase activity
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0061448 connective tissue development
GO:0061450 trophoblast cell migration
GO:1901163 regulation of trophoblast cell migration
GO:1901164 negative regulation of trophoblast cell migration
GO:1901652 response to peptide
GO:2000146 negative regulation of cell motility
GO:2000241 regulation of reproductive process
GO:2000242 negative regulation of reproductive process
GO:2001044 regulation of integrin-mediated signaling pathway
Molecular Function GO:0002020 protease binding
GO:0004857 enzyme inhibitor activity
GO:0004866 endopeptidase inhibitor activity
GO:0005125 cytokine activity
GO:0008083 growth factor activity
GO:0008191 metalloendopeptidase inhibitor activity
GO:0030414 peptidase inhibitor activity
GO:0061134 peptidase regulator activity
GO:0061135 endopeptidase regulator activity
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0005604 basement membrane
GO:0030141 secretory granule
GO:0031091 platelet alpha granule
GO:0031093 platelet alpha granule lumen
GO:0031983 vesicle lumen
GO:0034774 secretory granule lumen
GO:0044420 extracellular matrix component
GO:0060205 cytoplasmic membrane-bounded vesicle lumen
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG hsa04066 HIF-1 signaling pathway
Reactome R-HSA-1592389: Activation of Matrix Metalloproteinases
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-1474228: Degradation of the extracellular matrix
R-HSA-1474244: Extracellular matrix organization
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-6783783: Interleukin-10 signaling
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-114608: Platelet degranulation
R-HSA-76005: Response to elevated platelet cytosolic Ca2+
R-HSA-449147: Signaling by Interleukins
Summary
SymbolTIMP1
NameTIMP metallopeptidase inhibitor 1
Aliases TIMP; CLGI; tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor) ......
Chromosomal LocationXp11.3-p11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TIMP1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolTIMP1
NameTIMP metallopeptidase inhibitor 1
Aliases TIMP; CLGI; tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor) ......
Chromosomal LocationXp11.3-p11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TIMP1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.53 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolTIMP1
NameTIMP metallopeptidase inhibitor 1
Aliases TIMP; CLGI; tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor) ......
Chromosomal LocationXp11.3-p11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TIMP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.80.187
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-2.0860.65
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1560.96
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1620.699
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.120.963
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2070.952
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1040.885
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.5470.817
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.8190.756
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4990.876
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9650.844
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3710.0329
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TIMP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512200200.294
Summary
SymbolTIMP1
NameTIMP metallopeptidase inhibitor 1
Aliases TIMP; CLGI; tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor) ......
Chromosomal LocationXp11.3-p11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TIMP1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTIMP1
NameTIMP metallopeptidase inhibitor 1
Aliases TIMP; CLGI; tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor) ......
Chromosomal LocationXp11.3-p11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TIMP1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TIMP1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTIMP1
NameTIMP metallopeptidase inhibitor 1
Aliases TIMP; CLGI; tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor) ......
Chromosomal LocationXp11.3-p11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TIMP1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTIMP1
NameTIMP metallopeptidase inhibitor 1
Aliases TIMP; CLGI; tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor) ......
Chromosomal LocationXp11.3-p11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TIMP1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTIMP1
NameTIMP metallopeptidase inhibitor 1
Aliases TIMP; CLGI; tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor) ......
Chromosomal LocationXp11.3-p11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TIMP1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTIMP1
NameTIMP metallopeptidase inhibitor 1
Aliases TIMP; CLGI; tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor) ......
Chromosomal LocationXp11.3-p11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TIMP1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.